Table 1.
Demographic and clinical characteristics of patients at baseline.
| Total | |
|---|---|
| Total patients, N (%) | 88 (100) |
| Age, median (IQR)—years | 67 (58–73) |
| Age, N (%) | |
| < 50 years | 3 (3.4) |
| 50–70 years | 55 (62.5) |
| > 70 years | 30 (34.1) |
| Male sex, N (%) | 67 (76.1) |
| BMI (kg/m2), N (%) | |
| < 35 | 20 (22.7) |
| ≥ 35 | 6 (6.8) |
| Unknown | 62 (70.5) |
| Smoking, N (%) | |
| Never smokers | 13 (14.8) |
| Past/current smokers | 18 (20.5) |
| Unknown | 57 (64.8) |
| Number of comorbidities, N (%) | |
| 0 | 24 (27.3) |
| 1 | 32 (36.4) |
| 2 | 23 (26.1) |
| > 2 | 9 (10.2) |
| Comorbidities, N (%) | |
| Cardiovascular disease | 49 (55.7) |
| COPD | 6 (6.8) |
| Diabetes mellitus | 12 (13.6) |
| Autoimmune disease | 8 (9.1) |
| Cancer | 9 (10.2) |
| Oxygen support category, N (%) | |
| Ambient air | 8 (9.1) |
| Low-flow oxygen | 68 (77.3) |
| Non-invasive positive pressure ventilation | 10 (11.4) |
| Invasive ventilation | 1 (1.1) |
| Unknown | 1 (1.1) |
| PaO2/FiO2, N (%) | |
| > 300 | 4 (4.5) |
| 200 to < 300 | 19 (21.6) |
| 100 to < 200 | 33 (37.5) |
| < 100 | 9 (10.2) |
| Unknown | 23 (26.1) |
| Median PaO2/FiO2, (range) (IQR) | 160 (53–409) (122–210) |
| Lymphocyte count, N (%) | |
| > 1.0 × 109/L | 16 (18.2) |
| 0.8 × 109/L to 1.0 × 109/L | 9 (10.2) |
| 0.5 × 109/L to 0.8 × 109/L | 29 (33.0) |
| < 0.5 × 109/L | 29 (33.0) |
| Unknown | 5 (5.7) |
| Median D-dimer, (range), (IQR) | 2071 (85–35,000) (714–6227) |
| Previous therapies for Covid-19, N (%) | |
| Darunavir + ritonavir | 81 (92.0) |
| Hydroxychloroquine | 83 (94.3) |
| High-dose steroids | 76 (86.4) |
| Tocilizumab | 8 (9.1) |
IQR interquartile range; BMI body mass index; COPD chronic obstructive pulmonary disorder.